Budget Impact Analysis of Introducing Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the United States

Lisdexamfetamine dimesylate (LDX) 50 and 70 mg demonstrated efficacy in terms of reduced binge eating days per week in adults with moderate to severe binge eating disorder (BED) in 2 randomized control trials (RCTs). This analysis aimed to determine the budgetary impact of introducing LDX for the treatment of BED in the United States (US). A 1-year budget impact analysis from a US health care payer’s perspective was performed. The patient...